Prenetics Global Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Prenetics Global de winst en omzet met respectievelijk 76.9% en 93.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 84.5% per jaar.

Belangrijke informatie

76.9%

Groei van de winst

84.5%

Groei van de winst per aandeel

Healthcare winstgroei	20.9%
Inkomstengroei	93.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	19 Aug 2024

Recente toekomstige groei-updates

Recent updates

Prenetics Global Limited's (NASDAQ:PRE) Earnings Haven't Escaped The Attention Of Investors

Oct 12

Prenetics Global Limited (NASDAQ:PRE) Looks Just Right With A 29% Price Jump

May 29

Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues

Apr 08

Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%

Jan 07

Prenetics Global GAAP EPS of -$2.91, revenue of $51.72M

Sep 09

Winst- en omzetgroeiprognoses

NasdaqGM:PRE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	90	-9	N/A	N/A	1
12/31/2024	35	-43	N/A	N/A	1
6/30/2024	23	-43	N/A	N/A	N/A
3/31/2024	23	-50	N/A	N/A	N/A
12/31/2023	22	-54	-15	-14	N/A
9/30/2023	280	-18	N/A	N/A	N/A
6/30/2023	279	-23	N/A	N/A	N/A
3/31/2023	201	-168	N/A	N/A	N/A
12/31/2022	13	-226	8	15	N/A
9/30/2022	288	-278	N/A	N/A	N/A
6/30/2022	283	-343	-27	-19	N/A
3/31/2022	310	-209	N/A	N/A	N/A
12/31/2021	13	-219	2	13	N/A
9/30/2021	238	-94	3	15	N/A
6/30/2021	190	-4	-15	-6	N/A
3/31/2021	119	1	-14	-8	N/A
12/31/2020	65	-2	-6	-3	N/A
12/31/2019	9	-20	-2	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PRE de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PRE de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PRE de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PRE ( 93.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van PRE ( 93.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PRE naar verwachting over 3 jaar hoog zal zijn

Prenetics Global Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Prenetics Global Limited Reaffirms Revenue Guidance for the Year 2024

Consensus revenue estimates fall by 30%

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 17%

Consensus revenue estimates fall by 23%

Consensus revenue estimates decrease by 12%

Recent updates

Prenetics Announces the Launch of IM8 Health

Prenetics Global Limited's (NASDAQ:PRE) Earnings Haven't Escaped The Attention Of Investors

Prenetics Global Limited (NasdaqGM:PRE) acquired Europa Sports Partners, LLC.

Prenetics Global Limited Reaffirms Revenue Guidance for the Year 2024

Prenetics Global Limited (NASDAQ:PRE) Looks Just Right With A 29% Price Jump

New major risk - Share price stability

Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues

New minor risk - Profitability

Full year 2023 earnings released: US$4.83 loss per share (vs US$37.57 loss in FY 2022)

New minor risk - Share price stability

Prenetics Global Limited Announces Board Appointments

Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%

Consensus revenue estimates fall by 30%

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 17%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

New major risk - Shareholder dilution

Consensus revenue estimates fall by 23%

Prenetics Global Limited Appoints Joel Neoh as Chief Consumer Officer

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 12%

Forecast breakeven date moved forward to 2024

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2025

Prenetics Global Limited Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA

Prenetics Global Limited (NasdaqGM:PRE) agreed to acquire unknown majority stake in ACT Genomics Co., Ltd. from Sanomics Holdings Limited for $58.4 million.

Prenetics Global Limited (NasdaqGM:PRE) announces an Equity Buyback for $20 million worth of its shares.

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Prenetics Global Limited Revises Earnings Guidance for the Full Year 2022

Forecast to breakeven in 2024

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Prenetics Global Limited Provides Revenue Guidance for Third Quarter of 2022

Prenetics Global GAAP EPS of -$2.91, revenue of $51.72M

Prenetics Global Limited Launches Circle Snapshot, Simple At-Home Blood Tests Using the World's First Push-Button and Painless Blood Collection Device

Prenetics Group Limited Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong

First quarter 2022 earnings: EPS misses analyst expectations

Prenetics Group Limited completed the acquisition of Artisan Acquisition Corp. (NasdaqCM: ARTA) from Artisan LLC and others.

Prenetics Group Limited completed the acquisition of Artisan Acquisition Corp. (NasdaqCM: ARTA) from Artisan LLC and others.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven